{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:50:13Z","timestamp":1764064213430,"version":"3.45.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00108-025-01998-y","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:20:11Z","timestamp":1759926011000},"page":"1226-1232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Was ist gesichert in der medikament\u00f6sen Therapie der Herzinsuffizienz?","What is established in the medical treatment of heart failure?"],"prefix":"10.1007","volume":"66","author":[{"given":"Samira","family":"Soltani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"1998_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","author":"TA McDonagh","year":"2021","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2021) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failuredeveloped by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"1998_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijcard.2017.03.032","volume":"240","author":"DA Pascual-Figal","year":"2017","unstructured":"Pascual-Figal\u00a0DA, Ferrero-Gregori\u00a0A, Gomez-Otero\u00a0I et\u00a0al (2017) Mid-range left ventricular ejection fraction: clinical profile and cause of death in ambulatory patients with chronic heart failure. Int J Cardiol 240:265\u2013270. https:\/\/doi.org\/10.1016\/j.ijcard.2017.03.032","journal-title":"Int J Cardiol"},{"key":"1998_CR3","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.jacc.2009.08.019","volume":"54","author":"SM Dunlay","year":"2009","unstructured":"Dunlay\u00a0SM, Redfield\u00a0MM, Weston\u00a0SA et\u00a0al (2009) Hospitalizations after heart failure diagnosis a community perspective. J\u00a0Am Coll Cardiol 54:1695\u20131702. https:\/\/doi.org\/10.1016\/j.jacc.2009.08.019","journal-title":"J Am Coll Cardiol"},{"key":"1998_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00392-024-02396-4","volume":"113","author":"S von Haehling","year":"2024","unstructured":"von Haehling\u00a0S, Assmus\u00a0B, Bekfani\u00a0T et\u00a0al (2024) Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment. Clin Res Cardiol 113:1287\u20131305. https:\/\/doi.org\/10.1007\/s00392-024-02396-4","journal-title":"Clin Res Cardiol"},{"key":"1998_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/ejhf.2894","volume":"25","author":"SD Anker","year":"2023","unstructured":"Anker\u00a0SD, Usman\u00a0MS, Anker\u00a0MS et\u00a0al (2023) Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A\u00a0scientific statement of the heart failure association, the European heart rhythm association of the European society of cardiology, and the European society of hypertension. European J of Heart Fail 25:936\u2013955. https:\/\/doi.org\/10.1002\/ejhf.2894","journal-title":"European J of Heart Fail"},{"key":"1998_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1055\/a-1760-3843","volume":"147","author":"S Soltani","year":"2022","unstructured":"Soltani\u00a0S, B\u00f6hm\u00a0M, Frey\u00a0N et\u00a0al (2022) Fr\u00fche Implementierung der \u201eFantastic four\u201c bei Herzinsuffizienz mit reduzierter Ejektionsfraktion. Dtsch Med Wochenschr 147:931\u2013938. https:\/\/doi.org\/10.1055\/a-1760-3843","journal-title":"Dtsch Med Wochenschr"},{"key":"1998_CR7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/s0140-6736(22)02076-1","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa\u00a0A, Davison\u00a0B, Chioncel\u00a0O et\u00a0al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a\u00a0multinational, open-label, randomised, trial. Lancet 400:1938\u20131952. https:\/\/doi.org\/10.1016\/s0140-6736(22)02076-1","journal-title":"Lancet"},{"key":"1998_CR8","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh\u00a0TA, Metra\u00a0M, Adamo\u00a0M et\u00a0al (2023) 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart\u00a0J 44:3627\u20133639. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"1998_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/nejm199108013250501","volume":"325","author":"S Investigators","year":"1991","unstructured":"Investigators\u00a0S, Yusuf\u00a0S, Pitt\u00a0B et\u00a0al (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N\u00a0Engl J Med 325:293\u2013302. https:\/\/doi.org\/10.1056\/nejm199108013250501","journal-title":"N Engl J Med"},{"key":"1998_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/nejm198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. N\u00a0Engl J Med 316:1429\u20131435. https:\/\/doi.org\/10.1056\/nejm198706043162301","journal-title":"N Engl J Med"},{"key":"1998_CR11","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/s0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray\u00a0JJ, \u00d6stergren\u00a0J, Swedberg\u00a0K et\u00a0al (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:767\u2013771. https:\/\/doi.org\/10.1016\/s0140-6736(03)14283-3","journal-title":"Lancet"},{"key":"1998_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/nejmoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray\u00a0JJV, Packer\u00a0M, Desai\u00a0AS et\u00a0al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N\u00a0Engl J Med 371:993\u20131004. https:\/\/doi.org\/10.1056\/nejmoa1409077","journal-title":"N Engl J Med"},{"key":"1998_CR13","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/s0140-6736(99)04440-2","volume":"353","author":"Group\u00a0M-HS","year":"1999","unstructured":"Group\u00a0M-HS (1999) Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet 353:2001\u20132007. https:\/\/doi.org\/10.1016\/s0140-6736(99)04440-2","journal-title":"Lancet"},{"key":"1998_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad\u00a0F, McMurray\u00a0JJV, Krum\u00a0H et\u00a0al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N\u00a0Engl J Med 364:11\u201321. https:\/\/doi.org\/10.1056\/nejmoa1009492","journal-title":"N Engl J Med"},{"key":"1998_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/nejmoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray\u00a0JJV, Solomon\u00a0SD, Inzucchi\u00a0SE et\u00a0al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/nejmoa1911303","journal-title":"N Engl J Med"},{"key":"1998_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/circulationaha.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer\u00a0M, Anker\u00a0SD, Butler\u00a0J et\u00a0al (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a\u00a0reduced ejection fraction. Circulation 143:326\u2013336. https:\/\/doi.org\/10.1161\/circulationaha.120.051783","journal-title":"Circulation"},{"key":"1998_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/s0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg\u00a0K, Komajda\u00a0M, B\u00f6hm\u00a0M et\u00a0al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a\u00a0randomised placebo-controlled study. Lancet 376:875\u2013885. https:\/\/doi.org\/10.1016\/s0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"1998_CR18","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/nejmoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong\u00a0PW, Pieske\u00a0B, Anstrom\u00a0KJ et\u00a0al (2020) Vericiguat in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med 382:1883\u20131893. https:\/\/doi.org\/10.1056\/nejmoa1915928","journal-title":"N Engl J Med"},{"key":"1998_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2415471","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek\u00a0U, Gro\u00dfhennig\u00a0A, Schwab\u00a0J et\u00a0al (2025) Digitoxin in patients with heart failure and reduced ejection fraction. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2415471","journal-title":"N Engl J Med"},{"key":"1998_CR20","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrcardio.2015.109","volume":"12","author":"S von Haehling","year":"2015","unstructured":"von Haehling\u00a0S, Jankowska\u00a0EA, van Veldhuisen\u00a0DJ et\u00a0al (2015) Iron deficiency and cardiovascular disease. Nat Rev Cardiol 12:659\u2013669. https:\/\/doi.org\/10.1038\/nrcardio.2015.109","journal-title":"Nat Rev Cardiol"},{"key":"1998_CR21","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/nejmoa0908355","volume":"361","author":"SD Anker","year":"2009","unstructured":"Anker\u00a0SD, Colet\u00a0JC, Filippatos\u00a0G et\u00a0al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N\u00a0Engl J Med 361:2436\u20132448. https:\/\/doi.org\/10.1056\/nejmoa0908355","journal-title":"N Engl J Med"},{"key":"1998_CR22","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","volume":"36","author":"P Ponikowski","year":"2015","unstructured":"Ponikowski\u00a0P, van Veldhuisen\u00a0DJ, Comin-Colet\u00a0J et\u00a0al (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart\u00a0J 36:657\u2013668. https:\/\/doi.org\/10.1093\/eurheartj\/ehu385","journal-title":"Eur Heart J"},{"key":"1998_CR23","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/circulationaha.117.027497","volume":"136","author":"DJ van Veldhuisen","year":"2017","unstructured":"van Veldhuisen\u00a0DJ, Ponikowski\u00a0P, van der Meer\u00a0P et\u00a0al (2017) Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 136:1374\u20131383. https:\/\/doi.org\/10.1161\/circulationaha.117.027497","journal-title":"Circulation"},{"key":"1998_CR24","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/s0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski\u00a0P, Kirwan\u00a0B\u2011A, Anker\u00a0SD et\u00a0al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a\u00a0multicentre, double-blind, randomised, controlled trial. Lancet 396:1895\u20131904. https:\/\/doi.org\/10.1016\/s0140-6736(20)32339-4","journal-title":"Lancet"},{"key":"1998_CR25","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/s0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2023","unstructured":"Kalra\u00a0PR, Cleland\u00a0JGF, Petrie\u00a0MC et\u00a0al (2023) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 400:2199\u20132209. https:\/\/doi.org\/10.1016\/s0140-6736(22)02083-9","journal-title":"Lancet"},{"key":"1998_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.3833","author":"SD Anker","year":"2025","unstructured":"Anker\u00a0SD, Friede\u00a0T, Butler\u00a0J et\u00a0al (2025) Intravenous ferric carboxymaltose in heart failure with iron deficiency. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.3833","journal-title":"JAMA"},{"key":"1998_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03671-1","author":"SD Anker","year":"2025","unstructured":"Anker\u00a0SD, Karakas\u00a0M, Mentz\u00a0RJ et\u00a0al (2025) Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-03671-1","journal-title":"Nat Med"},{"key":"1998_CR28","doi-asserted-by":"publisher","unstructured":"Kempf T et\u00a0al Oral iron supplementation with ferric maltol improves iron deficiency anaemia in patiens with chronic heart failure. European J of Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.70029","DOI":"10.1002\/ejhf.70029"},{"key":"1998_CR29","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/s0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf\u00a0S, Pfeffer\u00a0MA, Swedberg\u00a0K et\u00a0al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:777\u2013781. https:\/\/doi.org\/10.1016\/s0140-6736(03)14285-7","journal-title":"Lancet"},{"key":"1998_CR30","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/nejmoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie\u00a0BM, Carson\u00a0PE, McMurray\u00a0JJ et\u00a0al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N\u00a0Engl J Med 359:2456\u20132467. https:\/\/doi.org\/10.1056\/nejmoa0805450","journal-title":"N Engl J Med"},{"key":"1998_CR31","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JGF Cleland","year":"2006","unstructured":"Cleland\u00a0JGF, Tendera\u00a0M, Adamus\u00a0J et\u00a0al (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart\u00a0J 27:2338\u20132345. https:\/\/doi.org\/10.1093\/eurheartj\/ehl250","journal-title":"Eur Heart J"},{"key":"1998_CR32","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/nejmoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Anand\u00a0IS et\u00a0al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N\u00a0Engl J Med 381:1609\u20131620. https:\/\/doi.org\/10.1056\/nejmoa1908655","journal-title":"N Engl J Med"},{"key":"1998_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/nejmoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt\u00a0B, Pfeffer\u00a0MA, Assmann\u00a0SF et\u00a0al (2014) Spironolactone for heart failure with preserved ejection fraction. N\u00a0Engl J Med 370:1383\u20131392. https:\/\/doi.org\/10.1056\/nejmoa1313731","journal-title":"N Engl J Med"},{"key":"1998_CR34","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/nejmoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Vaduganathan\u00a0M et\u00a0al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N\u00a0Engl J Med 391:1475\u20131485. https:\/\/doi.org\/10.1056\/nejmoa2407107","journal-title":"N Engl J Med"},{"key":"1998_CR35","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1001\/jamacardio.2023.5500","volume":"9","author":"P Palau","year":"2024","unstructured":"Palau\u00a0P, de la Espriella\u00a0R, Seller\u00a0J et\u00a0al (2024) \u03b2\u2011blocker withdrawal and functional capacity improvement in patients with heart failure with preserved ejection fraction. JAMA Cardiol 9:392\u2013396. https:\/\/doi.org\/10.1001\/jamacardio.2023.5500","journal-title":"JAMA Cardiol"},{"key":"1998_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","volume":"20","author":"C Bavishi","year":"2015","unstructured":"Bavishi\u00a0C, Chatterjee\u00a0S, Ather\u00a0S et\u00a0al (2015) Beta-blockers in heart failure with preserved ejection fraction: a\u00a0meta-analysis. Heart Fail Rev 20:193\u2013201. https:\/\/doi.org\/10.1007\/s10741-014-9453-8","journal-title":"Heart Fail Rev"},{"key":"1998_CR37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/nejmoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker\u00a0SD, Butler\u00a0J, Filippatos\u00a0G et\u00a0al (2021) Empagliflozin in heart failure with a\u00a0preserved ejection fraction. N\u00a0Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/nejmoa2107038","journal-title":"N Engl J Med"},{"key":"1998_CR38","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/nejmoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon\u00a0SD, McMurray\u00a0JJV, Claggett\u00a0B et\u00a0al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N\u00a0Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/nejmoa2206286","journal-title":"N Engl J Med"},{"key":"1998_CR39","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/nejmoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod\u00a0MN, Abildstr\u00f8m\u00a0SZ, Borlaug\u00a0BA et\u00a0al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N\u00a0Engl J Med 389:1069\u20131084. https:\/\/doi.org\/10.1056\/nejmoa2306963","journal-title":"N Engl J Med"},{"key":"1998_CR40","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/nejmoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod\u00a0MN, Petrie\u00a0MC, Borlaug\u00a0BA et\u00a0al (2024) Semaglutide in patients with obesity-related heart failure and type\u00a02 diabetes. N\u00a0Engl J Med 390:1394\u20131407. https:\/\/doi.org\/10.1056\/nejmoa2313917","journal-title":"N Engl J Med"},{"key":"1998_CR41","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2410027","author":"M Packer","year":"2024","unstructured":"Packer\u00a0M, Zile\u00a0MR, Kramer\u00a0CM et\u00a0al (2024) Tirzepatide for heart failure with preserved ejection fraction and obesity. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2410027","journal-title":"N Engl J Med"},{"key":"1998_CR42","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","volume":"45","author":"S von Haehling","year":"2024","unstructured":"von Haehling\u00a0S, Doehner\u00a0W, Evertz\u00a0R et\u00a0al (2024) Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart\u00a0J 45:3789\u20133800. https:\/\/doi.org\/10.1093\/eurheartj\/ehae479","journal-title":"Eur Heart J"},{"issue":"1","key":"1998_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland\u00a0JGF, Bunting\u00a0KV, Flather\u00a0MD, et\u00a0al. (2018) Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26-35. https:\/\/doi.org\/10.1093\/eurheartj\/ehx564","journal-title":"Eur Heart J"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01998-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01998-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01998-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T09:46:44Z","timestamp":1764064004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01998-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1998"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01998-y","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"type":"print","value":"2731-7080"},{"type":"electronic","value":"2731-7099"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"12 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J. Bauersachs hat von Novartis, Vifor, Bayer, Servier, Abiomed, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, Daichii Sankyo, CVRx, BMS, MSD, Amgen, Corvia Honorare f\u00fcr Vortrags- und Beratert\u00e4tigkeiten erhalten sowie Forschungsunterst\u00fctzung f\u00fcr die Institution von Zoll, CVRx, Vifor, Abiomed. S. Soltani hat Honorare f\u00fcr Vortr\u00e4ge von AstraZeneca und KelCon erhalten. Es bestehen keine Interessenkonflikte im Zusammenhang mit diesem Artikel.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}